

1 **Induction of poxviral immunity by synthetic MVA-based dual-antigen COVID-19 vaccine**

2 **COH04S1**

3 Flavia Chiuppesi*; John A. Zaia¹; Sandra Ortega Francisco; Minh Ly; Felix Wussow and Don J.

4 Diamond*

5 Department of Hematology and HCT and Hematologic Malignancies Research Institute, ¹Center

6 for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA,

7 91010.

8 *FC and DJD are co-corresponding authors

9

10 Corresponding Authors: F. Chiuppesi, fchiuppesi@coh.org; D.J. Diamond, ddiamond@coh.org.

11

12 Running title: Induction of poxviral immunity by COH04S1

13

14 **Summary**

15 The recent outbreak of monkeypox outside its endemic boundaries has attracted global
16 attention and prompted world leaders to reserve thousands of doses of the only approved third-
17 generation smallpox/monkeypox vaccine Jynneos, which is based on the highly attenuated
18 modified vaccinia Ankara (MVA) vector. Given the potential urgency to vaccinate individuals at
19 risk in both endemic and non-endemic countries to curtail further spread of the outbreak, there
20 is a legitimate need for substantial doses of smallpox/monkeypox vaccines. We previously
21 developed COH04S1, a multiantigen SARS-CoV-2 vaccine candidate built on a synthetic MVA
22 platform. COH04S1 was found to be safe and to induce SARS-CoV-2-specific immune
23 responses in healthy adults participating in a phase 1, blinded, randomized, placebo-controlled
24 clinical trial. Here we perform a retrospective analysis of vaccine-induced orthopoxvirus
25 immunity in a subgroup of volunteers enrolled in the phase 1 clinical trial that were vaccinated
26 with COH04S1 at different doses. At all dose levels, vaccination with COH04S1 resulted in
27 robust MVA-specific binding and neutralizing antibody responses, which were sustained over six
28 months post-vaccination. Similarly, both CD8+ and CD4+ T cells specific for MVA were induced
29 by COH04S1 vaccination and remained durable for at least six months. Given that both arms of
30 the immune response are thought to be involved in protection against orthopoxvirus infections,
31 our results indicate that COH04S1 or other sMVA-based vaccines may represent valuable
32 candidates for smallpox/monkeypox vaccination.

33 Introduction

34 The unforeseen 2022 Monkeypox outbreak outside of its endemic boundaries has worried
35 health officials and renewed interest in testing and stockpiling of a safe and effective smallpox
36 vaccine¹. Smallpox (or *variola major*), a poxvirus with a case-fatality rate of up to 30%, was
37 declared eradicated in 1980 after a very successful global vaccination campaign². Monkeypox
38 belongs to the same *orthopoxvirus* genus as smallpox and exists in two clades. The Central
39 African clade has a high mortality rate of 10%, while infection with the West African clade results
40 in about 1% case-fatality rate³. Monkeypox is endemic in some Central African countries, where
41 it causes more than 1,000 cases annually³⁻⁵. The recent worldwide outbreak with epicenter in
42 Europe caused by the less severe West African clade has resulted in more than 16,000 cases
43 globally (as of July 25th, 2022) with five reported deaths. The recently reported cases in children
44 and healthcare workers has prompted the WHO to declare monkeypox outbreak a global health
45 emergency.

46 Replication-competent vaccinia virus strains of different origin were used around the world for
47 the smallpox vaccination campaign, which ended in 1972⁶. In the US, vaccinia strain Dryvax
48 grown on calf skin formed the first-generation smallpox vaccine and was later substituted by
49 ACAM2000, which was plaque purified from Dryvax and produced using modern cell culture
50 technology. While ACAM2000 was highly immunogenic, it was associated with a high risk of
51 myocarditis/pericarditis (1 in 175 naïve adults), and this risk also extended to close contacts of
52 vaccinated subjects, posing a threat, albeit low, for children, pregnant women, and
53 immunocompromised individuals⁶. For this reason, use of ACAM2000 has been licensed with a
54 medication guide and its use restricted to designated U.S. military personnel and laboratory
55 researchers working with certain poxviruses.

56 Modified vaccinia Ankara (MVA) is a highly attenuated, replication-defective orthopoxvirus that
57 was derived from its parental strain chorioallantois vaccinia virus Ankara by over 500 passages

58 on chicken embryo fibroblasts⁷. MVA was developed as a third-generation smallpox vaccine and
59 has been safely administered at the end of the smallpox eradication campaign to more than
60 120,000 individuals, including children with immunodeficiencies and HIV infected individuals⁸.
61 Recently, Bavarian Nordic's proprietary MVA strain MVA-BN has been approved by the FDA as
62 a smallpox and monkeypox vaccine under the name of Jynneos based on a phase 3 non-
63 inferiority trial comparing one dose of ACAM2000 with two intramuscular doses of Jynneos⁹ as
64 well as nonhuman primate studies using a lethal monkeypox virus challenge¹⁰. Consequently,
65 Jynneos has been added to the Strategic National Stockpile (SNS) as a safer alternative to
66 ACAM2000 that could be administered to the broader population. Due to the recent monkeypox
67 outbreak, Jynneos is now offered in some countries as a prophylactic vaccine in at-risk subjects
68 and for ring vaccinations in possible contacts of infected individuals. Given its robust safety and
69 immunogenicity profile, MVA has also been extensively used as a viral vector for delivery of
70 heterologous antigens and tested as a vaccine against infectious diseases and cancer^{8,11-13}.

71 We developed a fully synthetic MVA (sMVA) platform based on the genome sequence
72 published by Antione *et al.*¹⁴ for reconstituting virus that is virtually identical to wild-type MVA in
73 terms of replication properties, host cell tropism, and immunogenicity¹⁵. Using this platform,
74 which allows rapid generation of sMVA recombinants encoding multiple transgenes, we
75 developed COH04S1, a multiantigen sMVA-based COVID-19 vaccine encoding for Spike (S)
76 and Nucleocapsid (N) antigens. COH04S1 has been extensively tested in small and large
77 animal models, demonstrating robust immunogenicity and protective efficacy against SARS-
78 CoV-2 and its variants through intramuscular and intranasal routes of vaccination¹⁵⁻¹⁷.
79 Additionally, COH04S1 has been tested in a phase I, randomized, placebo-controlled clinical
80 trial in healthy adults, showing a remarkable safety profile and resulting in the induction of
81 robust and durable humoral and cellular responses to both vaccine antigens^{18,19}. Currently,

82 COH04S1 is being evaluated in two phase 2 clinical trials in healthy adults and
83 immunocompromised patients (NCT04639466, NCT04977024).

84 Given the recent approval of MVA as a vaccine to prevent smallpox and monkeypox, we
85 evaluated whether COH04S1-vaccinated individuals, besides developing immunity to SARS-
86 CoV-2¹⁸, also mounted orthopoxviral-specific immunity. We found that COH04S1 vaccinees
87 developed robust orthopoxviral-specific humoral and cellular immune responses for up to six-
88 months post vaccination, suggesting that COH04S1 could be a unique dual-agent vaccine
89 candidate to simultaneously control the COVID-19 pandemic and the unforeseen global
90 monkeypox outbreak.

91

92 **Results**

93 **Study design to evaluate orthopoxviral immunity in COH04S1 vaccinees**

94 We retrospectively evaluated orthopoxviral-specific humoral and cellular immune responses for
95 up to six months after vaccination with sMVA COVID-19 vaccine candidate COH04S1 in a
96 subgroup of 20 volunteers enrolled in a phase 1 clinical trial aimed at testing safety and
97 immunogenicity of COH04S1 at different dose levels (DL) (NCT04639466)¹⁸. Subjects were
98 prime-boost vaccinated with low-dose (DL1, 1×10^7 plaque forming units [pfu]), medium-dose
99 (DL2, 1×10^8 pfu), or high-dose (DL3, 2.5×10^8 pfu) of vaccine. Of the 20 subjects vaccinated with
100 COH04S1, 15 (5 subjects/group) received two DL1, DL2, or DL3 vaccinations 28 days apart,
101 and 5 received two DL1 vaccinations 56 days apart with a placebo dose at day 28
102 (DL1/placebo/DL1). Four placebo-vaccinated subjects enrolled in the same trial were included
103 as controls. Subjects were not required to provide their smallpox vaccination status, and
104 poxvirus serostatus at enrollment was not evaluated. However, an exclusion criterion was any
105 poxvirus-vaccination in the six months before enrolling in the trial. Summary of study subjects,
106 vaccination schedule and age at enrollment is presented on Table S1.

107 **Orthopoxviral-specific binding antibodies induced in COH04S1-vaccinated subjects**

108 MVA-specific IgG binding antibodies in serum of COH04S1 vaccinated subjects were measured
109 against whole MVA virions by ELISA. Low binding (O.D.<0.4 nm) at low serum dilution (1:150)
110 was measured at baseline in most subjects (Figure S1). In contrast to all placebo control
111 volunteers, all subjects vaccinated with COH04S1 showed an increase in MVA-specific IgG
112 titers post-vaccination regardless of the dose vaccination regimen (Figure 1), demonstrating
113 potent vaccine-elicited orthopoxviral-specific humoral immunity. Elevated MVA-specific IgG
114 titers were measured following prime vaccination at all dose levels, although MVA IgG titers in
115 DL2 and DL3 subjects tended to be higher than those in DL1 subjects, indicating a dose
116 dependent response (Figure 1A-B). While DL1 cohorts had a seroconversion rate of 30-60%

117 following prime vaccination, DL2 and DL3 subjects showed 100% seroconversion after the first
118 dose (Figure 1C). MVA-specific IgG titers further increased in all vaccine cohorts following the
119 second dose resulting in similar responses in DL1 and DL2/3 subjects and 100%
120 seroconversion in all vaccine cohorts. MVA-specific IgG titers slowly declined over five-months
121 post vaccination in all vaccine cohorts, but they remained at elevated levels over baseline in all
122 subjects independent of the dose immunization regimen, except for one subject in the DL1
123 cohort. Notably, two subjects in the DL1 and DL3 cohorts - one subject born in 1971 and one
124 subject born in 1986 - had high IgG endpoint titers of 4,050 and 1,350 before vaccination,
125 possibly indicating pre-existing orthopoxviral immunity (Figure S1). These two subjects showed
126 particularly elevated MVA-IgG titers after only one vaccine dose and their MVA IgG titers
127 remained stable over six months post vaccination. These results overall demonstrate that
128 COH04S1-vaccinated subjects develop potent orthopoxviral-specific IgG antibody responses.

129 **Orthopoxviral-specific neutralizing antibodies induced in COH04S1-vaccinated subjects**

130 MVA-specific neutralizing antibody (NAb) responses were measured on epithelial cells using a
131 high-throughput microneutralization assay. Similar to the observed MVA IgG responses in DL1-
132 DL3 subjects, COH04S1-vaccinated subjects in all vaccine cohorts showed a strong increase in
133 MVA-specific NAb titers, consistent with potent vaccine-induced orthopoxviral-specific immunity
134 (Figure 2). Following prime vaccination, only a minor proportion of the DL1 subjects showed
135 elevated MVA-specific NAb titers, whereas all DL2 and DL3 subjects showed an increase in
136 MVA-specific NAb titers, confirming a dose-dependent vaccine effect after one dose (Figure 2A-
137 B). While the DL1 cohorts showed a seroconversion rate of 0-60% after the first vaccination,
138 DL2 and DL3 cohorts showed 100% seroconversion for MVA-specific NAb after the first dose
139 (Figure 2C). All subjects of the different vaccine cohorts developed robust MVA-specific NAb
140 titers at one month after the booster dose with NT50 titers ranging from 73 to >2,560 and a
141 median NT50 of 303, resulting in 100% seroconversion in all vaccine cohorts. DL2 and DL3

142 subjects tended to have slightly higher NAb titers than DL1 vaccinated volunteers. Similar to the
143 MVA IgG titers, MVA-specific NAb titers declined in all vaccine cohorts over five-months post-
144 second vaccination, but they remained above baseline in most subjects, resulting in a median
145 NT50 titer of 65 and comparable titers across vaccine groups. Only two volunteers in the DL2
146 and DL3 vaccine cohorts had undetectable MVA-specific NAb titers. Interestingly, the same two
147 subjects with high baseline MVA binding IgG titers had pre-vaccination NAb titers approaching
148 the NT50 detection limit of 20, suggesting pre-existing orthopoxvirus-specific NAb responses in
149 these vaccinees (Figure S2). Placebo-vaccinated volunteers had consistently undetectable
150 MVA-specific NAb throughout the observation period (Figure 2). These results demonstrate that
151 subjects vaccinated with COH04S1 at different dose levels develop robust and durable
152 orthopoxvirus-specific NAb responses.

153 **Orthopoxviral-specific cellular immunity induced in COH04S1-vaccinated subjects**

154 Orthopoxvirus-specific T cells were evaluated after the second dose by assessing co-
155 expression of IFN γ with CD107a or CD69 activation markers on MVA-stimulated T cells using
156 flow cytometry (Figures S3-S4). CD107a marks cells capable of cytotoxic effector functions
157 while CD69 is an early T cell activation marker that is transiently upregulated by activated T
158 cells. Low levels of activated CD8 $^{+}$ and CD4 $^{+}$ T cells secreting IFN γ upon MVA stimulation were
159 measured at baseline (Figures 3A and S5). COH04S1 vaccinees showed a significant increase
160 in CD107 $^{+}$ and CD69 $^{+}$ IFN γ -secreting CD8 $^{+}$ and CD4 $^{+}$ T cells at one month after the second
161 dose and they maintained significantly elevated levels of activated T cells over five months post-
162 boost (Figures 3A and S5). Similar levels of MVA-specific T cells were observed independently
163 of dose level (Figure S5). In contrast, placebo subjects showed no or only low percentage of
164 MVA-specific T cells (Figure S5).

165 Phenotypic analysis of activated MVA-specific T cell subsets revealed that both CD8 $^{+}$ and CD4 $^{+}$
166 T cell populations in COH04S1 vaccinees were mostly comprised of T effector memory (T_{EM})

167 cells (Figure 3B). Terminally differentiated T_{EM} cells (T_{EMRA}) comprised about 20% of the CD8⁺ T
168 cell population and were significantly higher than T_{EMRA} cells in the CD4⁺ population. Low
169 percentages of naïve and central memory (T_{CM}) T cells were measured in both CD8⁺ and CD4⁺
170 T cell populations. Comparable percentages of activated naïve/T_{CM}/T_{EM}/T_{EMRA} T cells were
171 measured across the different DL vaccine cohorts (Figure S6A-B). Finally, a similar phenotype
172 distribution with predominance of T_{EM/EMRA} over T_{CM} was observed in the CD8⁺ and CD4⁺ T cell
173 populations at one and five months post booster vaccination (Figure S6C-D). These results
174 demonstrate that at all tested dose levels vaccination with COH04S1 induces robust and
175 durable orthopoxvirus-specific cellular responses with a predominant effector memory
176 phenotype.

177 **Discussion**

178 In this report, we demonstrate that multiantigen sMVA-based SARS-CoV-2 vaccine COH04S1
179 induces robust orthopoxvirus-specific immunity in a sub-group of healthy adults vaccinated
180 twice at different dose levels during a Phase I clinical trial aimed at testing safety and
181 immunogenicity of COH04S1 as a COVID-19 vaccine¹⁸. Our findings show that COH04S1-
182 vaccinated volunteers at all tested dose levels develop robust MVA-specific humoral and
183 cellular responses that remain detectable for up to six months post vaccination, suggesting that
184 COH04S1 represents a unique and clinically tested vaccine candidate to confer SARS-CoV-2
185 and orthopoxvirus immunity to simultaneously control the COVID-19 pandemic and the current
186 global monkeypox outbreak.

187 MVA-specific binding and neutralizing antibodies developed in all volunteers after two vaccine
188 doses resulting in 100% seroconversion. Consistent with a dose-escalation trial using a wild-
189 type MVA²⁰ (ACAM3000), we found that post-prime antibody titers were affected by the vaccine
190 dose, with lower post-prime antibody titers in DL1 than in DL2/DL3 vaccinated subjects.
191 However, following the second dose, COH04S1 was similarly immunogenic at all DL tested.
192 Increased timing between vaccinations with DL1 did not affect the peak antibody response;
193 however, it seemed to marginally increase the magnitude of the long-term response compared
194 to volunteers vaccinated in a shorter interval, although a larger number of volunteers would be
195 needed to bolster this conclusion. No differences across DL were observed in magnitude and
196 phenotype of MVA-specific activated T cells indicating that the lowest dose was sufficient to
197 induce robust and durable cellular responses. This result is concordant with maximal induction
198 of SARS-CoV-2 S- and N-specific T cells by COH04S1 at all DL tested¹⁸.

199 As previously observed by others, early post-vaccine T cell response to orthopoxvirus antigens
200 was largely comprised of CD8⁺ T cells^{21,22}. Interestingly, COH04S1 induced higher MVA-specific
201 CD8⁺ than CD4⁺ T cells, which is opposite to the previously observed SARS-CoV-2 S- and N-

202 specific CD8⁺ and CD4⁺ T-cells induced by COH04S1¹⁸, indicating that different antigens can
203 preferentially activate different T cell subtypes even during concomitant antigen stimulation.
204 While it has been shown that T_{EM} are the predominant CD8⁺ subtype and T_{CM} the predominant
205 CD4⁺ T cell subtypes in SARS-CoV-2 infected or vaccinated individuals^{18,23,24}, we found that
206 MVA-specific T_{EM} cells were the predominant subtype in both CD8⁺ and CD4⁺ T cell populations
207 of COH04S1 vaccinees. Interestingly, T_{EM} cells, but not T_{CM} cells, have been demonstrated to
208 protect against peripheral infection with vaccinia virus²⁵, highlighting an important protective role
209 of T_{EM} cells in orthopoxviral infections. Comprehensive studies of long-term immunity to vaccinia
210 have shown that T_{EM} cells decay with time after antigen encounter while T_{CM} cells have a
211 greater capacity to persist *in vivo*²⁶. Whether the phenotype observed at six months post-
212 vaccination in COH04S1-vaccinated subjects is maintained long-term or whether T_{CM} cells may
213 overtake T_{EM} cells as the main MVA-specific T cell subpopulation can only be clarified in long-
214 term studies.

215 Smallpox and vaccinia immunity have been shown to be stable for decades after infection or
216 vaccination and to decline only slowly over time^{27,28}. Of the two volunteers born before 1972, the
217 year of the end of the smallpox vaccination campaign, only one had an indication of low levels
218 pre-existing poxviral immunity. However, both volunteers responded to two COH04S1 doses
219 with higher-than-average long-lasting humoral responses, suggesting that vaccination with
220 COH04S1 successfully recalled low-to-undetectable vaccinia immunity acquired 50 years or
221 more before, which resulted in more robust and durable responses than in naïve subjects.
222 Interestingly, one DL3 subject born in 1986, and therefore not subjected to smallpox vaccination
223 during childhood, showed low-level poxviral pre-existing humoral immunity at baseline. The
224 same subject had a drastic increase in MVA-specific humoral response post-prime vaccination,
225 and binding and NAb at five months post-boost were exceptionally high. It is plausible that this
226 subject was recently inoculated with vaccinia due to work exposure risk and that a combination

227 of high COH04S1 dose with short time since smallpox vaccination contributed to the elevated
228 MVA-specific responses. Importantly, this subject and the two volunteers born before 1972
229 developed robust SARS-CoV-2 S- and N-specific humoral and cellular responses¹⁸, suggesting
230 that vector-specific pre-existing immunity did not prevent induction of robust immunity to the
231 SARS-CoV-2 antigens of COH04S1.

232 Definition of correlates of protection against smallpox and monkeypox is complicated by the
233 contrasting findings emerged in the past decades. Orthopoxvirus-specific NAb but not CD8⁺ T
234 cells correlated with an attenuated Dryvax skin lesion or “take” at the inoculation site in one
235 study²⁹, and NAb were necessary and sufficient to protect monkeys against monkeypox in
236 another study³⁰. On the other hand, a study in mice demonstrated an important protective role of
237 T cell immunity in the absence of an antibody response³¹, and patients with defects in their T
238 cell responses are those at risk to develop severe progressive vaccinia disease when
239 vaccinated³². Consequently, it seems likely that a complex interplay of immunological factors
240 contributes to the establishment of immunity to orthopoxviruses and these immunological
241 correlates may vary based on species and viral strain. Therefore, it is encouraging that
242 COH04S1-vaccination induced a comprehensive MVA-specific immunological response in
243 vaccinated volunteers.

244 Intramuscular doses of both ACAM3000 (1×10^7 pfu) and Jynneos (1×10^8 pfu) have been shown
245 to result in a significantly attenuated response to a Dryvax “take” in human challenge
246 studies^{9,29,33}. Considering that COH04S1 induced comparable humoral and cellular responses
247 post-boost at all dose levels tested, it is possible that COH04S1 would confer similar protection
248 to wild-type MVA vaccines against challenge starting from the lowest dose tested. However,
249 non-inferiority clinical studies with immunological endpoints⁹ and challenge studies in non-
250 human primates^{34,35} will be necessary to determine protective efficacy of COH04S1 against
251 smallpox and monkeypox.

252 Major limitation of the study is the small number of subjects included in the study. Nonetheless,
253 achievement of seroconversion and cellular responses in all subjects post-boost independent of
254 vaccine dose indicates that vaccination with COH04S1 induces robust MVA-specific immunity.
255 Because of biosafety limitations, we have not used vaccinia or monkeypox viruses for
256 assessment of vaccine immunogenicity. However, magnitude of MVA- and vaccinia-specific
257 humoral immunity have been shown to be equivalent and vaccinia and monkeypox NAb targets
258 to be >94% conserved, indicating high degree of antibody cross-recognition between
259 orthopoxviruses^{20,29,36}. Additionally, a comparison of binding and NAb titers induced by
260 COH04S1 with titers measured in the WHO “International Standard for Anti-Smallpox Serum”
261 63/024³⁷ was not possible since the product is currently not available in the NIBSC repository.
262 Finally, to measure NAb, we utilized a high throughput neutralization assay based on the use of
263 purified MVA intracellular mature virions, which are the main viral form liberated by cell lysis. We
264 have not evaluated vaccine-mediated neutralization of extracellular enveloped virions although
265 this viral form is believed to be responsible for vaccinia virus inter-host dissemination³⁸.

266 Following the recent monkeypox outbreak numerous countries have rushed ordering Jynneos
267 for their nationals in need for a total of more than 3 million doses³⁹. Additionally, the eventuality
268 of a mass monkeypox vaccination campaign in endemic African countries raises the issue of
269 vaccine supply shortage and equitable distribution. Consequently, there is an urgency to
270 replenish stockpiles around the world with safe and effective third generation
271 smallpox/monkeypox vaccines. The finding that COH04S1 induces robust and durable
272 orthopoxviral-specific immunity represent the fundamental preliminary result for allowing
273 COH04S1 and other sMVA-based vaccines to be tested in non-inferiority clinical trials as
274 vaccines against smallpox/monkeypox.

275 **Methods**

276 **Human subjects**

277 COH04S1 is a dual-antigen COVID-19 vaccine candidate based on a synthetic MVA
278 platform^{15,16,18}. COH04S1 immunogenicity was investigated at City of Hope (COH) as part of a
279 clinical protocol (IRB#20447) approved by an external Institutional Review Board (Advarra IRB).
280 This open-label and randomized, placebo controlled, phase 1 clinical study is registered
281 (NCT04639466). Among others, exclusion criteria included age<18 or >55, previous SARS-
282 CoV-2 infection, BMI<18 or >35, underlying health conditions, and poxvirus vaccination within a
283 six-months period. All subjects gave informed consent at enrollment. Out of the 51 subjects who
284 received one or two doses of COH04S1, 5 subjects were selected from each dose group, for a
285 total of 20 subjects, based on 2 doses regimen and availability of frozen PBMCs samples.
286 Subjects received two doses of COH04S1 at days 0 and 28. Five subjects were vaccinated with
287 dose level (DL) 1 (1×10^7 pfu), five with DL2 (1×10^8 pfu), and five with DL3 (2.5×10^8 pfu).
288 Additional five subjects received DL1 at day 0, placebo at day 28, and another DL1 at day 56.
289 Four volunteers who received placebo at days 0 and 28 were included in the study. Two
290 subjects -one in DL1/DL1 group and one in DL2/DL2 group- were born before 1972 and
291 therefore may have had been previously vaccinated against smallpox. Study population is
292 described on Table S1.

293 **MVA IgG Endpoint ELISA**

294 MVA-specific binding antibodies were evaluated by ELISA. ELISA plates (3361, Corning) were
295 coated overnight at 4°C with $1 \mu\text{g/mL}$ of MVA expressing Venus fluorescent marker (MVA-
296 Venus)¹³ in PBS pH 7.4. Plates were washed 5X with wash buffer (0.1% Tween-20/PBS), then
297 blocked with 250 $\mu\text{l/well}$ of assay buffer (0.5% casein/154mM NaCl/10mM Tris-HCl/0.1%
298 Tween-20 [pH 7.6]/8% Normal goat serum) for 2 hours 37°C. After washing, 3-fold diluted heat-

299 inactivated serum in blocking buffer was added to the plates starting from a dilution of 1:150.
300 Plates were wrapped in foil and incubated 2 hours at 37°C. Plates were washed and 1:3,000
301 dilution of anti-human IgG HRP secondary antibody (BioRad 204005) in assay buffer was added
302 for 1 hour at room temperature. Plates were washed and developed with 1 Step TMB-Ultra
303 (Thermo Fisher 34029). After 2-4 minutes the reaction was stopped with 1M H₂SO₄ and 450nm
304 absorbance was immediately quantified on FilterMax F3 (Molecular Devices). Endpoint titers
305 were calculated as the highest dilution to have an absorbance >0.100 nm. Seroconversion was
306 defined a three or more times increase in baseline titer.

307 **MVA neutralization assay**

308 ARPE-19 cells were seeded in 96-well plates (1.5 × 10⁴ cells/well). The following day, 2-fold
309 serial dilutions of serum starting from 1:10 were incubated for 2 h with MVA-Venus (multiplicity
310 of infection [MOI]=2). The serum–virus mixture was added to the cells in duplicate wells and
311 incubated for 24 h. After the 24 h incubation period, the cells were imaged using Leica DMI8
312 inverted microscope. Pictures from each well were processed using Image-Pro Premier (v9.2;
313 Media Cybernetics) and fluorescent cells corresponding to infection events were counted. The
314 neutralization titer for each dilution was calculated as follows: $NT = \frac{1}{1 - (\text{fluorescent cells with}$
315 $\text{immune sera} / \text{fluorescent cells without immune sera})} \times 100$. The titers that gave 50%
316 neutralization (NT50) were calculated by determining the linear slope of the graph plotting NT
317 versus serum dilution by using the next higher and lower NT using Office Excel (v2019).
318 Seroconversion was defined as an increase of two or more times the baseline titer⁹.

319 **Quantification of vaccine-induced MVA specific T cells**

320 Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using Ficoll and
321 counted using Luna-FL cell counter (Logos Biosystems). Frozen PBMCs were thawed, counted
322 and 1X10⁶ PBMCs were stimulated with MVA-Venus (MOI=1) for 24 hours in a total volume of

323 200 μ l of RPMI media with 5% of human serum in a 96 wells plate. Unstimulated cells and PHA
324 (20 μ g/ml) were used as negative and positive controls, respectively. Anti-CD107a-APC, Golgi
325 Plug (Brefeldin A) and Golgi Stop (Monesin) were added 4 hours before staining. Cells were
326 washed with PBS and stained 15 min at room temperature with Live and dead near IR, anti-
327 CD3-FITC, anti-CD4-BV421, anti-CD8-BV605, anti-CD69-PE, anti-CCR7-PE/Dazzle 594 and
328 anti-CD45-PerCP. After washing, cells were permeabilized with Fix/Perm (BD) for 20 minutes at
329 4°C. Cells were washed with Perm/Wash (BD) and intracellular stained with anti-IFN γ -PECy7
330 for 30 minutes at 4°C, washed and resuspend in FACS buffer until acquisition. Cells were
331 acquired in Attune NxT cytometer (Thermofisher) and data was analyzed with Flow Jo X
332 software following the gating strategy described in Figure S3. Only one out of five DL3
333 volunteers had available PBMCs samples for the analysis.

334 **Statistical analysis**

335 Statistical analysis was performed using GraphPad Prism 8.3.0. Differences in humoral
336 responses across groups were compared using Kruskal-Wallis test followed by Dunn's multiple
337 comparison test. T cell percentages at different time-points were compared using two-tailed
338 Wilcoxon rank test. Differences in T cell subsets were evaluated using 2-way ANOVA followed
339 by Sidak's multiple comparison test.

340 **Contributors**

341 Study conceptualization: FC, FW, DJD. Study design: FC, FW. Immunological analysis: FC,

342 SOF, ML. Manuscript writing: FC, FW, DJD. Clinical PI: JAZ. All authors contributed to and

343 approved the final version of this manuscript.

344

345 **Declaration of interests**

346 While unknown whether publication of this report will aid in receiving grants and contracts, it is
347 possible that this publication will be of benefit to City of Hope (COH). COH had no role in the
348 conceptualization, design, data collection, analysis, decision to publish, or preparation of the
349 manuscript. DJD and FW are co-inventors on a patent application covering the design and
350 construction of the synthetic MVA platform (PCT/US2021/016247). DJD, FW, and FC are co-
351 inventors on a patent application covering the development of a COVID-19 vaccine
352 (PCT/US2021/032821). DJD is a consultant for GeoVax. All other authors declare no competing
353 interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 under the
354 name of GEO-CM04S1.

355

356

357 **Data sharing**

358 We support data sharing of the individual de-identified participant data that underlie the results
359 reported in this article. Study protocols can be shared upon request by the corresponding
360 author.

361

362 **Acknowledgements**

363 The Authors would like to thank all the participants who volunteered in the study and all the
364 investigators and study site personnel who assisted in the clinical trial completion. Funding was
365 provided by the Carol Moss Foundation, donors Julie and Roger Baskes, Judd Malkin, Michael
366 Sweig, and the City of Hope Integrated Drug Development Venture program. We acknowledge
367 and thank Christoph Pittius and Yuriy Shostak (Research Business Development, City of Hope)
368 for excellent project management. We thank Christina Ulloa (Department of Hematology & HCT,
369 City of Hope) for excellent support of investigators and meeting coordination.


370

371 References


- 372 1 Kozlov, M. Monkeypox vaccination begins - can the global outbreaks be contained?
373 *Nature*, doi:10.1038/d41586-022-01587-1 (2022).
- 374 2 Fenner, F. The global eradication of smallpox. *Med J Aust* **1**, 455-455,
375 doi:10.5694/j.1326-5377.1980.tb135034.x (1980).
- 376 3 Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox
377 outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* **13**, e0007791,
378 doi:10.1371/journal.pntd.0007791 (2019).
- 379 4 Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after
380 smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl*
381 *Acad Sci U S A* **107**, 16262-16267, doi:10.1073/pnas.1005769107 (2010).
- 382 5 Durski, K. N. *et al.* Emergence of Monkeypox - West and Central Africa, 1970-2017.
383 *MMWR Morb Mortal Wkly Rep* **67**, 306-310, doi:10.15585/mmwr.mm6710a5 (2018).
- 384 6 Jacobs, B. L. *et al.* Vaccinia virus vaccines: past, present and future. *Antiviral Res* **84**, 1-
385 13, doi:10.1016/j.antiviral.2009.06.006 (2009).
- 386 7 Volz, A. & Sutter, G. Modified Vaccinia Virus Ankara: History, Value in Basic Research,
387 and Current Perspectives for Vaccine Development. *Adv Virus Res* **97**, 187-243,
388 doi:10.1016/bs.aivir.2016.07.001 (2017).
- 389 8 Verheust, C., Goossens, M., Pauwels, K. & Breyer, D. Biosafety aspects of modified
390 vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
391 *Vaccine* **30**, 2623-2632, doi:10.1016/j.vaccine.2012.02.016 (2012).
- 392 9 Pittman, P. R. *et al.* Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine
393 against Smallpox. *N Engl J Med* **381**, 1897-1908, doi:10.1056/NEJMoa1817307 (2019).
- 394 10 Earl, P. L. *et al.* Rapid protection in a monkeypox model by a single injection of a
395 replication-deficient vaccinia virus. *Proc Natl Acad Sci U S A* **105**, 10889-10894,
396 doi:10.1073/pnas.0804985105 (2008).
- 397 11 Chiappesi, F. *et al.* Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To
398 Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus
399 in Mice. *J Virol* **92**, doi:10.1128/JVI.01012-18 (2018).
- 400 12 La Rosa, C. *et al.* MVA vaccine encoding CMV antigens safely induces durable
401 expansion of CMV-specific T cells in healthy adults. *Blood* **129**, 114-125,
402 doi:10.1182/blood-2016-07-729756 (2017).
- 403 13 Wussow, F. *et al.* Human cytomegalovirus vaccine based on the envelope gH/gL
404 pentamer complex. *PLoS Pathog* **10**, e1004524, doi:10.1371/journal.ppat.1004524
405 (2014).
- 406 14 Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic
407 sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.
408 *Virology* **244**, 365-396, doi:10.1006/viro.1998.9123 (1998).
- 409 15 Chiappesi, F. *et al.* Development of a multi-antigenic SARS-CoV-2 vaccine candidate
410 using a synthetic poxvirus platform. *Nat Commun* **11**, 6121, doi:10.1038/s41467-020-
411 19819-1 (2020).
- 412 16 Chiappesi, F. *et al.* Synthetic multiantigen MVA vaccine COH04S1 protects against
413 SARS-CoV-2 in Syrian hamsters and non-human primates. *NPJ Vaccines* **7**, 7,
414 doi:10.1038/s41541-022-00436-6 (2022).
- 415 17 Wussow, F. *et al.* COH04S1 and Beta Sequence Modified Vaccine Protect Hamsters
416 From SARS-CoV-2 Variants. *iScience*, 104457, doi:10.1016/j.isci.2022.104457 (2022).
- 417 18 Chiappesi, F. *et al.* Safety and immunogenicity of a synthetic multiantigen modified
418 vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and
419 randomised, phase 1 trial. *Lancet Microbe*, doi:10.1016/S2666-5247(22)00027-1 (2022).

- 420 19 Chiuppesi, F. *et al.* Vaccine-induced spike- and nucleocapsid-specific cellular responses
421 maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. *iScience*,
422 104745, doi:10.1016/j.isci.2022.104745 (2022).
- 423 20 Wilck, M. B. *et al.* Safety and immunogenicity of modified vaccinia Ankara (ACAM3000):
424 effect of dose and route of administration. *J Infect Dis* **201**, 1361-1370,
425 doi:10.1086/651561 (2010).
- 426 21 Miller, J. D. *et al.* Human effector and memory CD8+ T cell responses to smallpox and
427 yellow fever vaccines. *Immunity* **28**, 710-722, doi:10.1016/j.immuni.2008.02.020 (2008).
- 428 22 Amara, R. R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. Long-lived poxvirus immunity,
429 robust CD4 help, and better persistence of CD4 than CD8 T cells. *J Virol* **78**, 3811-3816,
430 doi:10.1128/jvi.78.8.3811-3816.2004 (2004).
- 431 23 Gao, Y. *et al.* Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron
432 variant. *Nat Med*, doi:10.1038/s41591-022-01700-x (2022).
- 433 24 Neidleman, J. *et al.* SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper
434 Function, Lack of Terminal Differentiation, and High Proliferation Potential. *Cell Rep Med*
435 **1**, 100081, doi:10.1016/j.xcrm.2020.100081
436 S2666-3791(20)30102-6 (2020).
- 437 25 Bachmann, M. F., Wolint, P., Schwarz, K., Jager, P. & Oxenius, A. Functional properties
438 and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor
439 alpha and CD62L. *J Immunol* **175**, 4686-4696, doi:10.4049/jimmunol.175.7.4686 (2005).
- 440 26 Puissant, B. & Combadiere, B. Keeping the memory of smallpox virus. *Cell Mol Life Sci*
441 **63**, 2249-2259, doi:10.1007/s00018-006-6313-2 (2006).
- 442 27 Hanna, W. & Baxby, D. Studies in smallpox and vaccination. 1913. *Rev Med Virol* **12**,
443 201-209, doi:10.1002/rmv.361 (2002).
- 444 28 Crotty, S. *et al.* Cutting edge: long-term B cell memory in humans after smallpox
445 vaccination. *J Immunol* **171**, 4969-4973, doi:10.4049/jimmunol.171.10.4969 (2003).
- 446 29 Seaman, M. S. *et al.* Effect of vaccination with modified vaccinia Ankara (ACAM3000) on
447 subsequent challenge with Dryvax. *J Infect Dis* **201**, 1353-1360, doi:10.1086/651560
448 (2010).
- 449 30 Edghill-Smith, Y. *et al.* Smallpox vaccine-induced antibodies are necessary and
450 sufficient for protection against monkeypox virus. *Nat Med* **11**, 740-747,
451 doi:10.1038/nm1261 (2005).
- 452 31 Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. Highly attenuated smallpox vaccine
453 protects mice with and without immune deficiencies against pathogenic vaccinia virus
454 challenge. *Proc Natl Acad Sci U S A* **101**, 4590-4595, doi:10.1073/pnas.0401165101
455 (2004).
- 456 32 Bray, M. & Wright, M. E. Progressive vaccinia. *Clin Infect Dis* **36**, 766-774,
457 doi:10.1086/374244 (2003).
- 458 33 Frey, S. E. *et al.* Clinical and immunologic responses to multiple doses of IMVAMUNE
459 (Modified Vaccinia Ankara) followed by Dryvax challenge. *Vaccine* **25**, 8562-8573,
460 doi:10.1016/j.vaccine.2007.10.017 (2007).
- 461 34 Earl, P. L. *et al.* Immunogenicity of a highly attenuated MVA smallpox vaccine and
462 protection against monkeypox. *Nature* **428**, 182-185, doi:10.1038/nature02331 (2004).
- 463 35 Stittelaar, K. J. *et al.* Modified vaccinia virus Ankara protects macaques against
464 respiratory challenge with monkeypox virus. *J Virol* **79**, 7845-7851,
465 doi:10.1128/JVI.79.12.7845-7851.2005 (2005).
- 466 36 Ahmed, S. F., Sohail, M. S., Quadeer, A. A. & McKay, M. R. Vaccinia virus vaccination is
467 expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. *BioRxiv*,
468 doi:10.1101/2022.06.23.497143 (2022).

- 469 37 Anderson, S. G. & Skegg, J. The international standard for anti-smallpox serum. *Bull*
470 *World Health Organ* **42**, 515-523 (1970).
- 471 38 Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular
472 enveloped vaccinia virus. *J Gen Virol* **83**, 2915-2931, doi:10.1099/0022-1317-83-12-
473 2915 (2002).
- 474 39 HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox
475 Preparedness. doi:[https://www.hhs.gov/about/news/2022/07/01/hhs-orders-2-point-5-](https://www.hhs.gov/about/news/2022/07/01/hhs-orders-2-point-5-million-more-doses-jynneos-vaccine-for-monkeypox-preparedness.html)
476 [million-more-doses-jynneos-vaccine-for-monkeypox-preparedness.html](https://www.hhs.gov/about/news/2022/07/01/hhs-orders-2-point-5-million-more-doses-jynneos-vaccine-for-monkeypox-preparedness.html) (2022).
- 477
- 478




479
 480 **Figure 1. MVA-specific binding IgG in COH04S1 vaccinees. A-B.** Binding antibodies. MVA-
 481 specific IgG titers were measured by ELISA in subjects before vaccination, post-prime
 482 vaccination, and at one and five months post-booster vaccination with COH04S1 at dose-level
 483 (DL) 1 (DL1/DL1 and DL1/placebo/DL1), DL2 (DL2/DL2), and DL3 (DL3/DL3). Subjects who
 484 received placebo vaccination were used as negative controls. Black triangles in B indicate time
 485 point of vaccination in DL1/DL1, DL2/DL2, and DL3/DL3 groups. Purple triangles indicate time
 486 of DL1 vaccinations in DL1/placebo/DL1 group. Red asterisks indicate subjects in DL1/DL1 and
 487 DL2/DL2 cohorts that were born before 1972. Black asterisk indicates the DL3 subject born in
 488 1986 with suspected orthopoxvirus pre-existing immunity. Kruskal-Wallis test followed by
 489 Dunn's multiple comparison test was used in A (*= $p < 0.05$, **= $p < 0.01$). **C.** Seroconversion rate.
 490 Shown is the percentage of seroconverted volunteers with MVA-specific NAb titers ≥ 3 -fold
 491 above baseline at different time points post-vaccination with COH04S1.



492

493 **Figure 2. MVA-specific neutralizing response in COH04S1 vaccinees. A-B.** Neutralizing
 494 antibodies (NAb). MVA-specific NAb titers preventing 50% infection (NT50) were measured with
 495 a high-throughput neutralization assay. NAb were measured before vaccination, post-prime
 496 vaccination, and at one and five months post-booster vaccinations with COH04S1 at dose-level
 497 (DL) 1 (DL1/DL1 and DL1/placebo/DL1), DL2 (DL2/DL2), and DL3 (DL3/DL3). Subjects who
 498 received placebo vaccination were used as negative controls. Black triangles in B indicate time
 499 of vaccinations in DL1/DL1, DL2/DL2, and DL3/DL3 groups. Purple triangles indicate time of
 500 DL1 vaccinations in DL1/placebo/DL1 group. Red asterisks indicate subjects in DL1/DL1 and
 501 DL2/DL2 cohorts that were born <1972. Black asterisk indicates the DL3 subject born in 1986
 502 with suspected orthopoxvirus pre-existing immunity. Kruskal-Wallis test followed by Dunn's
 503 multiple comparison test was used in A (*= $p < 0.05$, **= $p < 0.01$). **C.** Seroconversion rate. Shown
 504 is the percentage of seroconverted volunteers with MVA-specific NAb titers above baseline at
 505 different time points post-vaccination with COH04S1.



506

507 **Figure 3. MVA-specific T cell response in COH04S1 vaccinees. A.** IFN γ^+ /CD107 $^+$ and
 508 IFN γ^+ /CD69 $^+$ CD8 $^+$ and CD4 $^+$ T cell percentages were measured by cytofluorimetry in PBMC
 509 samples at baseline, and at one and five months post-booster vaccinations with COH04S1 at all
 510 dose levels. Activated T cell percentages at one and five months (mo) post-boost were
 511 compared to baseline levels using two-tailed Wilcoxon signed-rank test. **B.** Phenotypic analysis
 512 of antigen-specific T lymphocytes was performed using samples collected one month post-

513 second dose. Shown are percentages of naïve, central memory (T_{CM}), effector memory (T_{EM}),
514 and terminally differentiated effector memory (T_{EMRA}) T cells measured in $IFN\gamma^+/CD69^+$ $CD8^+$
515 and $CD4^+$ T cell populations. 2-way ANOVA followed by Sidak's multiple comparison test was
516 used to compare groups. P values are indicated in the figure. In A-B box plots extend from the
517 25th to the 75th percentiles, median values are shown as a line, whiskers extend from minimum
518 to maximum values.

519